Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is scheduled to be releasing its earnings data before the market opens on Tuesday, October 31st. Analysts expect Momenta Pharmaceuticals to post earnings of ($0.47) per share for the quarter.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.50). The firm had revenue of $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The firm’s revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) earnings per share. On average, analysts expect Momenta Pharmaceuticals to post $-0.75 EPS for the current fiscal year and $-1.08 EPS for the next fiscal year.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at 13.90 on Tuesday. The company has a 50-day moving average of $15.89 and a 200-day moving average of $15.83. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.75 and a 12 month high of $19.90. The firm’s market cap is $1.03 billion.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/24/momenta-pharmaceuticals-inc-mnta-scheduled-to-post-earnings-on-tuesday.html.

A number of research analysts have issued reports on MNTA shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 target price for the company. Stifel Nicolaus reissued a “buy” rating and set a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Barclays PLC reissued an “equal weight” rating and set a $16.00 target price (down from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Finally, BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Three analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $15.00.

In other news, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the sale, the president now directly owns 269,231 shares of the company’s stock, valued at approximately $4,057,311.17. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now directly owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,663 shares of company stock valued at $1,414,498. Company insiders own 4.40% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.